- Home
- UUU vs BLRX Comparison
UUU vs BLRX Comparison
Compare UUU & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UUU | BLRX |
|---|---|---|
| Founded | 1969 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2M | 12.6M |
| IPO Year | 2025 | 2010 |
Fundamental Metrics
Financial Performance| Metric | UUU | BLRX |
|---|---|---|
| Price | $6.09 | $2.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | ★ 40.3K | 8.4K |
| Earning Date | 02-19-2026 | 03-23-2026 |
| Dividend Yield | ★ 16.42% | N/A |
| EPS Growth | ★ 229.41 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $23,563,554.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.39 | N/A |
| 52 Week Low | $1.65 | $2.30 |
| 52 Week High | $8.27 | $7.77 |
Technical Indicators
Market Signals| Indicator | UUU | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 64.58 | 44.86 |
| Support Level | $4.00 | $2.66 |
| Resistance Level | $6.10 | $3.93 |
| Average True Range (ATR) | 0.44 | 0.15 |
| MACD | 0.10 | 0.01 |
| Stochastic Oscillator | 79.21 | 33.76 |
Price Performance
Historical ComparisonAbout UUU Universal Security Instruments Inc.
Universal Safety Products Inc is a U.S.-based importer and distributor of home safety devices such as ventilation fans and ground fault circuit interrupters.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.